Skip to main
NEO

NeoGenomics (NEO) Stock Forecast & Price Target

NeoGenomics (NEO) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

NeoGenomics is a comprehensive provider of cancer diagnostic testing with a wide range of services, experienced team of professionals, and a strong network of labs. Despite margin and launch challenges, the company has consistently delivered strong revenue growth with a positive outlook for the future, driven by expanding capabilities and partnerships with pharma companies. With a strong leadership team, potential upside drivers and a dominant position in the market, NeoGenomics has the potential to continue its growth trajectory and solidify its position as a leading player in the oncology space. However, risks such as potential setbacks in reimbursement or patent litigation, negative changes in reimbursement, and potential competition from more focused companies should be monitored closely.

Bears say

NeoGenomics is facing major risks due to reduction in research and development budgets, reduced purchasing from healthcare and hospital customers, increased regulatory hurdles, and reliance on emerging markets. These risks have the potential to hinder revenue and profitability growth. Additionally, the company's current guidance for 4Q25 may not reflect sustainable growth, leading to potential disappointment when full results are announced, further contributing to a negative outlook.

NeoGenomics (NEO) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeoGenomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeoGenomics (NEO) Forecast

Analysts have given NeoGenomics (NEO) a Buy based on their latest research and market trends.

According to 7 analysts, NeoGenomics (NEO) has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeoGenomics (NEO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.